Granules India inaugurates two advanced Centres of Excellence at IIT Hyderabad

Written By :  Ruchika Sharma
Published On 2025-12-01 07:50 GMT   |   Update On 2025-12-01 07:50 GMT
Advertisement

Hyderabad: Granules India Limited has inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.

The inauguration was led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, Uma Chigurupati, Executive Director, Granules India Limited & Prof. B S Murty, Director, IITH Ascelis Center of Excellence for Peptide Development and Characterization, established under Ascelis Peptides, the CDMO arm of Granules, this Centre will drive the development of cosmetic, therapeutic, and pharmaceutical peptides.
Advertisement
It is Ascelis’ first development and characterization facility in India and is equipped for primary, secondary, and tertiary structure characterization. The Center brings advanced analytical and process development capabilities in-house and will work in collaboration with Granules' Swiss-based R&D facility Senn Chemicals,
Granules Center of Excellence for Particle Engineering, This Centre will advance polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. It replaces earlier external and ad-hoc development with a dedicated research platform that enables first-to-file opportunities, enhances formulation performance, and supports the creation of proprietary technologies for regulated markets.
Speaking at the inauguration, Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, said, “Scientific excellence and rigorous research have always shaped our longterm strategy at Granules. The launch of these Centres of Excellence significantly strengthens our capabilities in peptides and advanced material sciences, areas that will define the next wave of pharmaceutical innovation. With specialised infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness and deliver meaningful value to our partners and patients worldwide.”

Read also: Granules Pharma incorporates wholly owned subsidiary in Canada

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News